LLY
StockEli Lilly and Co
- HQ
- US
- Sector
- Pharmaceuticals
- Issued
- 1985-01-13
- Shares out.
- 942M
Performance
1 h agoKey statistics
1 h ago- Market cap
- $1.02T
- Enterprise value
- $1.05T
- P/E (TTM)
- 40.16
- Forward P/E
- 27.51
- P/E (annual)
- 49.19
- PEG
- 1.37
- P/B
- 38.29
- P/S (TTM)
- 14.05
- P/S (annual)
- 15.58
- EV / EBITDA
- 31.38×
- EV / Revenue
- 14.58×
- EPS (TTM)
- $28.15
- EPS (annual)
- $22.95
- Basic EPS (TTM)
- $28.15
- Book value / share
- $28.09
- Gross margin
- 82.83%
- Operating margin
- 43.63%
- Net margin
- 34.99%
- Return on equity (ROE)
- 101.31%
- Return on assets (ROA)
- 22.73%
- Return on investment (ROI)
- 37.71%
- EBITDA / share
- $37.37
- Revenue / share (TTM)
- $80.64
- Revenue growth (TTM YoY)
- +47.44%
- Revenue growth (Q YoY)
- +55.55%
- EPS growth (TTM YoY)
- +128.83%
- Dividend yield (indicated)
- 0.64%
- Dividend yield (TTM)
- 0.55%
- Dividend / share (TTM)
- $5.91
- Payout ratio
- 22.10%
- Current ratio
- 1.58
- Quick ratio
- 0.78
- Debt / equity
- 1.60
- LT debt / equity
- 1.54
- Beta
- 0.52
- Volatility (3M)
- 37.57%
Analyst ratings
1 h agoEarnings
1 h agoRelated news
1 h ago- Yahoo·4 d agocompanySupreme Court Verdict Tests Eli Lilly Valuation And Legal Risk Outlook
United States Supreme Court upholds a $220 million Medicaid fraud verdict against Eli Lilly under the False Claims Act. Decision stems from a whistleblower case and concludes a 12 year legal dispute. Ruling is described as the first jury verdict against a pharmaceutical company under this statute. Eli Lilly, NYSE: LLY, now has a material legal setback sitting alongside a large market valuation, with the stock recently trading around $1,126.80. The company has very large multi year share...
- Yahoo·4 d agocompanyEli Lilly (LLY): Top Healthcare Stock Pick of Claude AI
We just covered the Claude Stock Portfolio: Top 10 Stocks to Buy According to AI Chatbot. Eli Lilly and Company (NYSE:LLY) ranks #2 (see Claude Stock Portfolio: Top 5 Stocks to Buy According to AI Chatbot). Number of Hedge Funds: 137 Eli Lilly and Company (NYSE:LLY) is among the top stock picks of the Claude […]
- CNBC·4 d agocompanyPortal Innovations' Flavin on M&A activity in the pharma space
John Flavin, Portal Innovations, joins 'Fast Money' to talk pharma M&A activities.
- Yahoo·4 d agocompanyLLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst?
Eli Lilly hits a record high after CVS expands coverage for Foundayo and Zepbound, boosting obesity drug access and raising the stakes in its rivalry with NVO.
- Yahoo·4 d agocompanyLilly Reopens Zepbound Access For 10 Million US Patients
CVS restores broader Zepbound coverage after price cuts, putting Wegovy and Zepbound on equal footing.
- Yahoo·4 d agocompanyHealthcare ETFs to Buy as Eli Lily Steps Into Vaccine Market With $4B Bet
LLY's $4B vaccine push is boosting interest in healthcare ETFs like IHE with heavy exposure to the drugmaker.
- Yahoo·4 d agocompanyStock Market News for May 29, 2026
Wall Street closed higher on Thursday, driven by tech and healthcare stocks.
- Yahoo·4 d agocompanyJim Cramer on Eli Lilly: “Brilliant Management”
Eli Lilly and Company (NYSE:LLY) was among the stocks Jim Cramer discussed on Mad Money, highlighting several companies with market caps over a trillion dollars. Cramer highlighted the company’s new cholesterol drug’s Phase 3 trial, as he commented: Finally, the 11th largest US company, holy cow…. smaller than Micron but still just over 1 trillion, […]
